On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss. Other companies working on MASH candidates include 89bio Inc (NASDAQ:ETNB), Akero Therapeutics Inc (NASDAQ:AKRO), and Viking Therapeutics Inc (NASDAQ:VKTX). The Phase 2 SYNERGY-NASH trial studied three doses (5 mg, 10 mg or 15 mg) of ...